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Abstract
Background: The UK Thalassaemia Register records births, deaths and selected clinical data of
patients with thalassaemia who are resident in the UK. A study of survival and causes of death was
undertaken which aimed to include the possible impact of T2* cardiovascular magnetic resonance
(CMR).
Methods:  The Register was updated to the end of 2003, copies of death certificates were
obtained, and causes of death in beta thalassaemia major were extracted. In addition, patients who
had T2* CMR assessment of cardiac iron load and/or received the oral iron chelator deferiprone
were identified from clinical records.
Results: The main causes of death were anaemia (before 1980), infections, complications of bone
marrow transplantation and cardiac disease due to iron overload. From 1980 to 1999 there were
12.7 deaths from all causes per 1,000 patient years. Forty per cent of patients born before 1980
had T2* cardiovascular magnetic resonance between 2000 and 2003, and 36% of these patients
were prescribed deferiprone before end of 2003. In 2000–2003, the death rate from all causes fell
significantly to 4.3 per 1,000 patient years (-62%, p < 0.05). This was mainly driven by the reduction
in the rate of deaths from iron overload which fell from 7.9 to 2.3 deaths per 1,000 patient years
(-71%, p < 0.05).
Conclusion: Since 1999, there has been a marked improvement in survival in thalassaemia major
in the UK, which has been mainly driven by a reduction in deaths due to cardiac iron overload. The
most likely causes for this include the introduction of T2* CMR to identify myocardial siderosis and
appropriate intensification of iron chelation treatment, alongside other improvements in clinical
care.
Introduction
Over the past 50 years the prevalence of thalassaemia
major has increased throughout North-West Europe,
reflecting immigration from endemic areas [1]. In the
Published: 25 September 2008
Journal of Cardiovascular Magnetic Resonance 2008, 10:42 doi:10.1186/1532-429X-10-42
Received: 11 September 2008
Accepted: 25 September 2008
This article is available from: http://www.jcmr-online.com/content/10/1/42
© 2008 Modell et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Journal of Cardiovascular Magnetic Resonance 2008, 10:42 http://www.jcmr-online.com/content/10/1/42
Page 2 of 8
(page number not for citation purposes)
United Kingdom (UK) a database of affected children was
created in the 1960s to assess the prevalence of the disor-
der among Cypriots in London [2], and to describe its nat-
ural history [3]. This was subsequently developed into the
UK Thalassaemia Register, a clinical and research tool
designed to promote equitable high quality care by simul-
taneously collecting audit data, and disseminating spe-
cialist knowledge to clinics with small numbers of
patients. The Register attracted a very high level of collab-
oration from doctors treating patients with thalassaemia,
and is considered to be over 97% complete [4].
Regular transfusion to maintain a mean haemoglobin in
the normal range, which became standard treatment in
the 1960s [3], gives good quality of life in the short term,
but leads to death from transfusional iron overload at
between 12 and 24 years of age. In the UK, the iron chelat-
ing agent deferoxamine became available in 1964 [5].
Daily intramuscular injection of 20–25 mg/kg/day stabi-
lised body iron load at around 0.65 mg/kg body weight
[6], and improved survival [7]. In 1976 it was shown that
subcutaneous infusion of a higher dose using a portable
syringe driver could stabilise body iron load at around 0.3
mg/kg body weight [8], and by 1980 subcutaneous infu-
sion of an average daily dose of 40–45 mg/kg/day (usually
over 8 to 12 hours on five nights per week) had become
standard care in the UK. Bone marrow transplantation for
thalassaemia was initiated in the UK in 1984 [9], and has
been requested by most families with a compatible related
donor since the mid-nineties [4]. The oral iron chelating
agent deferiprone was first used in clinical practice in
1987 [10], and its use in the UK has gradually increased,
particularly for patients who cannot tolerate deferoxam-
ine treatment [11], and for patients with cardiac iron load-
ing. A second oral iron chelator, Deferasirox, was
introduced into clinical trials in the UK only after the data
reported here was collected. The reliable identification of
cardiac siderosis was made possible with the T2* cardio-
vascular magnetic resonance (CMR) technique which
became available in the UK in 1999 [12], and this has
been a driver for changes in, and intensification of, iron
chelator therapy. Also in 1999, the UK Register informa-
tion on continuing high mortality in thalassemia was cir-
culated to all collaborating doctors. These data were
published 18 months later [7]. The poor patient survival
was disappointing given the general availability of defer-
oxamine treatment, and was considered largely due to
non-compliance to the burdensome iron chelation regi-
men among adolescent and young adult patients. How-
ever, cardiac disease and death had also occurred among
compliant patients with a low serum ferritin and low liver
iron concentration, suggesting that these measures are not
always a reliable guide to cardiac iron load [12-14]. The
communication indicated that improved methods for
administering deferoxamine and availability of the oral
iron chelating agent deferiprone now allowed more toler-
able patient-specific iron chelation regimens, and rein-
forced the existing recommendation to refer patients
regularly to an expert centre for assessment and advice. In
the light of these events of 1999, we analysed of the fre-
quency and the causes of death for before and after this
year.
Methods
The UK Thalassaemia Register provides a minimum data
set, drawn from the clinical records of patients with tha-
lassaemia. The scientific method is fully described else-
where [4]. Underpinning informatics methods are aligned
with current approaches to electronic healthcare records,
with a view to integration in the long-term. Ethical
approval for this study was obtained.
Numbers of deaths
At the beginning of 2003, participating doctors were
requested to update the current status of their patients
(alive, transferred away, new patient, deceased), and at the
end of 2003 they were asked to notify any deaths that had
occurred during the year. Thus at the end of 2003 infor-
mation on number of deaths was complete (though infor-
mation on new births was incomplete because it usually
takes 1–3 years for a patient to present and be registered).
The register has not been further updated since this time
primarily because of funding issues, and therefore no fur-
ther data after the end of 2003 is currently available.
Causes of deaths
The Register already held a summary of the entire clinical
record and a copy of the death certificate for deaths prior
to 1981 [3]: causes of death identified from the notes and
from the death certificate were consistent. Copies of the
remaining death certificates were supplied by the Office of
National Statistics. UK death certificates include three sec-
tions for cause of death (eg cardiomyopathy due to iron
overload due to thalassaemia major). This was fully com-
pleted in all but one case, where the only cause of death
given was "thalassaemia major". All causes were entered
in the Register. When the cause was infection unrelated to
bone marrow transplantation, the patient's doctor or hos-
pital was asked for any available information on the
organism responsible.
Calculation of death rates
Data was analysed by 10-year birth cohort to the end of
1999, and for the four years 2000 to the end of 2003. Mor-
tality rate (deaths per 1,000 patient years) was calculated
for each birth cohort for each decade or part of a decade.
The significance of differences in death rates was assessed
by calculating 95% confidence intervals: absence of over-
lap is considered statistically significant at the usual 5%
level.Journal of Cardiovascular Magnetic Resonance 2008, 10:42 http://www.jcmr-online.com/content/10/1/42
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Calculation of life-expectancy
Patients alive at the beginning of each decade were classi-
fied by 5-year age groups (0–4, 5–9 etc). The percentage in
each age group who died in the next 5 years was calcu-
lated, and cumulative mortality (survival) was presented
graphically.
CMR
T2* CMR was performed using standard techniques as
first described by Anderson [12], and refined by West-
wood [15] and Maceira [16]. Cardiac siderosis was
defined as a myocardial T2* < 20 ms [12].
Deployment of deferiprone and CMR
T2* cardiovascular magnetic resonance (CMR) was intro-
duced in 1999 at Royal Brompton Hospital in London,
where it was first developed [12]. T2* CMR was applied
rapidly in clinical management from 2000 as the benefits
became clear of direct visualisation of cardiac siderosis as
a guide to the need for, and a means of assessing the
response to intensified iron chelation therapy. Increased
iron chelation was deployed with intensified deferoxam-
ine or deferiprone [17], as monotherapy or in combina-
tion, by clinicians in consultation with individual
patients. Increasingly the decision to treat with
deferiprone was made in response to the finding of car-
diac iron loading. To document the deployment of CMR
and deferiprone, data was extracted on patients with tha-
lassaemia who had had CMR by end-2003, and the iron
chelation therapy they were receiving at the time.
Results
Survival analysis
The UK Thalassaemia Register includes all patients with a
serious thalassaemia (Table 1). However, this report is
limited to the 850 recorded patients with thalassaemia
major (transfusion dependent before four years of age).
Table 2 shows the causes of the 206 deaths in this group
by decade. The commonest cause of death was iron over-
load (111 cases, 54% of total) with all death certificates
reporting a cardiac cause. There were 19 deaths (9% of
total) from infection. The organism responsible was
known in only seven cases: there were two deaths from
Yersinia infection, one from pneumococcal septicaemia,
and four from Klebsiella meningitis. Thirty three patients
(16% of total) died from anaemia, but only 3 of these
deaths occurred after 1975: one 17-year-old declined fur-
ther treatment, and 2 were young children whose parents
took them for an extensive stay abroad. Death due to com-
plications of bone marrow transplantation (21 patients,
10% of total) was first reported in 1984 and has now
become rare. There were two deaths (1%) due to malig-
nancy in young children (one leukaemia, one medullob-
lastoma). More recently, two patients (1%) with hepatitis
C infection died from hepatoma aged 39 and 47. One
woman (0.5%) died aged 39 from carcinoma of the
breast. The 16 deaths (8%) due to "other causes" included
three from liver disease, three from disturbed coagulation
(two bleeding, one clotting), two from diabetes, two from
renal failure, one from congenital heart disease, one from
lung disease, one from cardiac tamponade caused by a
misplaced Hickman line, two due to transfusion of
infected blood, and one due to a road traffic accident.
CMR and iron chelator
At the end of 2003, 40% of thalassemia patients born
before 1980 had undergone T2* CMR. Of these patients,
36% were prescribed deferiprone, in the majority of cases
following the results of the CMR scan showing cardiac
siderosis. All remaining patients were taking deferoxam-
ine only, as deferasirox was only introduced into clinical
trials in the UK after 2003.
Death rates
Tables 3, 4, 5 and 6 shows numbers of deaths, number of
patient years, and death rates (deaths per 1,000 patient
years) from all causes and from iron overload by decade.
The final columns of Table 5 and 6 show a steady decrease
in death rate from iron overload among patients 10–20
years old. However, in 1990–99 this was offset by an
increased death rate among older patients, giving an aver-
age death rate from iron overload of 7.9 per 1000 patient
years from 1980 to 1999. Since 2000 there has been a
marked decrease in deaths from iron overload at any age,
giving an average rate of 2.3 per 1,000 patient years (-
71%, p < 0.05, figure 1). Table 7 compares average death
rates by decade. There was no significant difference in
death rates from all causes or from iron overload in the
three decades starting in 1970, 1980 and 1990. Since the
beginning of 2000 there has been a significant fall in
death rate from all causes (-62%, p < 0.05).
Discussion
Reduced Mortality in Thalassemia
The data show a significant improvement in survival in
thalassaemia major since 1999. In the younger patient
group this is largely due to improved survival following
bone marrow transplantation, and in older patients (born
Table 1: Patients on the UK Thalassaemia Register at the end of 
2003.
Diagnosis Alive Dead Total
Beta thalassaemia major 644 206 850
Beta thalassaemia intermedia 138 20 158
Hb E/beta thalassaemia 73 7 80
Alpha thalassaemia major 1 0 1
Total 856 233 1,089
Alpha thalassaemia major = homozygous alpha zero thalassaemiaJournal of Cardiovascular Magnetic Resonance 2008, 10:42 http://www.jcmr-online.com/content/10/1/42
Page 4 of 8
(page number not for citation purposes)
before 1980) it is dominated by decreased mortality from
cardiac iron overload. It is likely that multiple factors have
contributed to the improving survival of older patients.
Whilst their relative contributions cannot be determined
with certainty, the most relevant factor appears to be the
introduction of the use of T2* CMR for assessing cardiac
iron loading, thereby identifying patients at highest risk
who require intensified iron chelation treatment, this
being linked to improved chelation and the increasing use
of the oral iron chelator deferiprone [18,19]. Other con-
tributing factors include the improved application of con-
ventional methods for assessing cardiac function and
intensive deferoxamine therapy [20,21], communication
of the need for vigilance of heart disease to treating doc-
tors, the referral of patients to expert centres for assess-
ment, and the promotion of new developments to
patients, nurses and doctors by the UK Thalassaemia Soci-
ety [22].
A similar change with improved survival has been
reported from Italy, where T2* CMR has been available
since 2002, and has been definitely linked to deferiprone
use [23,24]. A comparable improvement in survival has
also been observed in Cyprus, where T2* CMR was intro-
duced in 2004, and where the most significant change in
treatment has also been the increasing use of deferiprone,
usually in combination with deferoxamine [25]. In both
these countries, the use of T2* CMR may also have con-
tributed to improved identification and treatment of
patients with myocardial siderosis. These observations are
consistent with the greater tolerability of an oral drug, the
superior ability of deferiprone compared with deferoxam-
ine to remove iron rapidly from the heart [17], and the
substantial effect of deferoxamine and deferiprone when
used in combination for increasing iron excretion
[26,27]., The use of T2* CMR has also highlighted the
large number of patients with cardiac iron overload who
Table 3: Death rates from all causes in thalassaemia major in the UK, by decade.
All 
Causes
Patient years Deaths, all causes
Year of 
birth
Births Before 
1960
1960–
69
1970–
79
1980–
89
1990–
99
2000–
03
Total Before 
1960
1960 – 
69
1970 – 
79
1980 – 
89
1990 – 
99
2000 – 
03
Total
Before 
1960
55 263 454 312 186 140 48 1403 6 7 17 10 3 0 43
1960–
69
166 842 1,452 1,205 948 346 4,793 15 15 32 19 2 83
1970–
79
216 1,107 2,081 1,814 665 5,667 5 8 35 3 51
1980–
89
212 1,234 1,982 750 3,966 6 15 5 26
1990–
99
172 952 683 1,635 2 1 3
2000–
2003
29 92 92 0 0
TOTAL 850 263 1,296 2,871 4,706 5,836 2,584 17,556 6 22 37 56 74 11 206
Table 2: Changes over time in numbers and causes of death in thalassaemia major in the UK.
Period
Cause of death 1950 – 59 1960 – 69 1970 – 79 1980 – 89 1990 – 99 2000 – 03 Total
I r o n  o v e r l o a d 1 2 13 74 66 1 1 1
Anaemia 6 17 9 1 33
BMT complication 5 15 1 21
I n f e c t i o n 145631 9
Malignancy 1 1 2 1 5
O t h e r 2284 1 6
Unknown 11
TOTAL 6 22 37 56 74 11 206
% iron overload 0 4.5 56.8 66.1 62.2 54.5 53.9
BMT = Bone marrow transplantationJournal of Cardiovascular Magnetic Resonance 2008, 10:42 http://www.jcmr-online.com/content/10/1/42
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are on chronic deferoxamine treatment [12,19], who are
at risk particularly when myocardial T2* is less than 10 ms
[28], sometimes even with good compliance [13]. The
widespread application of T2* CMR has been realised
[29,30], and when combined with appropriate chelation
management [18,28,31,32], the current observations
optimistically suggest that, with sustained collaborative
effort, it may now be possible to eliminate death from
transfusional iron overload.
Changing Life Expectancy
Survival data is often presented as Kaplan Meier curves,
which show cumulative mortality in patient cohorts born
in specified periods [7,20,33], but this focus on attrition
rate can be pessimistic, especially in clinical discussions
with older patients. In practice, the more optimistic pic-
ture of the current life-expectancy of living patients, as cal-
culated by life insurance companies, is more useful for
patients and health workers. Figure 2 compares life
expectancy for patients who were alive at the beginning of
1970, 1980, 1990 and 2000, based on mortality in the
subsequent five years (four years for the period 2000–
2003). The calculation shows an average life-expectancy
of 17 years in 1970, 27 years in 1980 and 37 years in
1990. Since 2000, over 80% of patients have a life expect-
ancy of more than 40 years. It is still not possible to esti-
mate ultimate life-expectancy, and the prognosis for older
patients remains "open-ended".
Non-Cardiac Causes of Death
No deaths have occurred in the UK as a direct result of the
use of either deferoxamine or deferiprone. However, sev-
eral deaths indirectly related to deferoxamine therapy
have been reported – two due to infection with Yersinia
enterocolitica (which uses the iron chelate ferrioxamine as
an iron source) [34], and one from cardiac tamponade
due to a misplaced Hickman line. More time would be
needed to assess the likelihood of death indirectly related
to deferiprone.
With a reduction in deaths from iron overload, infection
may become a leading cause of death in thalassaemia in
the future. Splenectomy increases risk of infection with
Pneumococcus and Haemophilus influenzae and deferox-
Table 5: Death rates from iron overload per 1,000 patient years in thalassaemia major in the UK, by decade.
Iron 
overlo
ad
Patient years Deaths from iron overload
Year of 
birth
Births Before 
1960
1960–
69
1970–
79
1980–
89
1990–
99
2000–
03
Total Before 
1960
1960 – 
69
1970 – 
79
1980 – 
89
1990 – 
99
2000 – 
03
Total
Before 
1960
5 5 2 6 3 4 5 4 3 1 2 1 8 6 1 4 0 4 8 1 4 0 3 011 4 6202 3
1960–
69
166 842 1,452 1,205 948 346 4,793 0 7 27 15 1 50
1970–
79
216 1,107 2,081 1,814 665 5,667 0 4 23 1 28
1980–
89
2 1 2 1 , 2 3 4 1 , 9 8 2 7 5 0 3 , 9 6 6 0641 0
1990–
99
172 952 683 1,635 0 0 0
2000–
2003
29 92 92 0 0
TOTAL 850 263 1,296 2,871 4,706 5,836 2,584 17,556 1 21 37 46 6 111
Table 4: Death rates from all causes per 1,000 patient years in thalassaemia major in the UK, by decade.
All Causes Deaths, all causes per 1,000 patient years
Year of birth Births Before 1960 1960 – 69 1970 – 79 1980 – 89 1990 – 99 2000 – 03 Total
Before 1960 55 22.8 15.4 54.5 53.8 21.4 0.0 30.6
1960–69 166 17.8 10.3 26.6 20.0 5.8 17.3
1970–79 216 4.5 3.8 19.3 4.5 9.0
1980–89 212 4.9 7.6 6.7 6.6
1990–99 172 2.1 1.5 1.8
2000–2003 29 0.0 0.0
TOTAL 850 22.8 17.0 12.9 11.9 12.7 4.3 11.7Journal of Cardiovascular Magnetic Resonance 2008, 10:42 http://www.jcmr-online.com/content/10/1/42
Page 6 of 8
(page number not for citation purposes)
amine therapy increases risk of infection with Yersinia
enterocolitica, and there have been at least 3 deaths from
these infections. However, the most frequently isolated
organism was Klebsiella. An increased risk of Klebsiella
infection in thalassaemia has previously been reported
from South East Asia [35,36], and some forms of Kleb-
siella can use deferoxamine as an iron source [37], but it
remains to be clarified whether Klebsiella infection is
related to iron chelation therapy. There are two main risks
for thalassaemics with a Klebsiella infection: acutely ill
patients are typically admitted to the nearest hospital
where there is usually little experience with thalassaemia,
and current treatment practice focuses on a likely gram
positive infection. Patients and doctors should be alert to
the fact that an acutely ill patient with thalassaemia
requires antibiotics active against both gram negative and
gram positive organisms. Hepatocarcinoma is also a grow-
ing problem for hepatitis C positive patients, and
improved antiviral treatments are needed. Fortunately,
transmission of hepatitis C by blood transfusion is now
very rare, so this risk may be limited to older patients.
Conclusion
The control of cardiac iron overload as the major cause of
death in thalassaemia major has been greatly improved by
the deployment of T2* CMR, which makes cardiac sidero-
sis visible both to clinicians and patients, in combination
with appropriate alterations in iron chelator treatment.
This includes the wider deployment of the oral iron chela-
tor deferiprone both as monotherapy and in combination
with deferoxamine. These two factors are likely to be the
main drivers for the improvement in mortality identified
in the UK thalassemia register. Should cardiac disease be
conquered, then attention will inevitably need to be
focussed on other causes of mortality, notably infections.
These data suggest that widespread use of T2* CMR [38],
or newer related sequences [39-41], has great potential to
reduce the cardiac mortality in chronically transfused
beta-thalassemia major.
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infusion of deferoxamine was standard practice after 1980. In 
1999, T2* CMR was introduced in the UK, and doctors car-
ing for thalassemia patients were informed of the high cardiac 
death rate and new options for iron chelation therapy. There 
has been a 71% reduction in the annualized death-rate from 
iron overload since 2000.
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Comparison of life expectancy for patients who were 
alive at the beginning of 1970, 1980, 1990 and 2000, 
based on mortality in the subsequent five years (four 
years for the period 2000–2003). Curves are con-
structed by calculating the proportion of patients in each 
group who were alive at the time indicated and were still 
alive at the end of the next 5 years. For the four year interval 
2000–2003, mortality was multiplied by 1.25 to adjust to 5 
years. The calculation shows an average life-expectancy of 17 
years in 1970, 27 years in 1980 and 37 years in 1990. Since 
2000 over 80% of patients have a life expectancy of more 
than 40 years. It is still not possible to estimate ultimate life-
expectancy, and the prognosis for older patients remains 
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